@article{8c7469b7dba44c73a143ffc418949eb8,
title = "Has the Enemy {"}MET{"} Its Match? Subgroup Analysis Results from VISION Study",
abstract = "Emerging therapies have recently received approval for the treatment of MET exon 14 skipping non-small cell lung cancer (NSCLC). Further characterization of these therapies, such as tepotinib, is needed to identify patient subgroups most likely to derive benefit from these novel agents.",
author = "Samuel Rosner and Spira, \{Alexander I.\}",
note = "Funding Information: A.I. Spira reports grants from Astellas Pharma, Newlink Genetics, AbbVie, Astex Pharmaceuticals, Loxo, Arch Therapeutics, Plexxicon, Daiichi Sankyo, ADCT, and Rubius; grants and personal fees from MedImmune, Novartis, Incyte, CytomX Therapeutics, Bristol-Myers Squibb, Gritstone, Amgen, Janssen Oncology, and Mirati Therapeutics; personal fees from Jazz Pharmaceuticals, Janssen Research \& Development, Array BioPharma, Merck, and Bayer HealthCare; and other support from Eli Lilly and Company, Virginia Cancer Specialist, and NEXT Oncology VA outside the submitted work. No disclosures were reported by the other author. Publisher Copyright: {\textcopyright} 2022 American Association for Cancer Research.",
year = "2022",
month = mar,
day = "15",
doi = "10.1158/1078-0432.CCR-21-4109",
language = "English (US)",
volume = "28",
pages = "1055--1057",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",
}